INSMINSMED Incvs its industry peers
A metric-by-metric comparison of INSMED Inc against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INSMEsta | $24.1B#13 | — | 33.2x#12 | 39.8x#10 | 66.7%#2 | -39.7%#14 | -205.6%#14 | -175.8%#14 | -141.2%#12 | 3#3 | -42.0%#14 | — |
| VRTX | $142.8B#4 | 32.8x#5 | 7.1x#5 | 11.9x#8 | 8.9%#9 | 838.1%#3 | 34.8%#3 | 19.5%#6 | 25.0%#4 | — | 32.4%#10 | — |
| AMGN | $250.1B#2 | 28.7x#4 | 21.4x#10 | 6.8x#4 | 10.0%#8 | 88.5%#7 | 24.7%#8 | 66.0%#1 | 15.1%#7 | — | 58.2%#6 | 2.0%#1 |
| GILD | $207.9B#3 | — | 15.9x#9 | 7.1x#5 | 2.4%#10 | 1672.9%#2 | 34.0%#4 | 65.3%#2 | 25.7%#3 | — | 42.7%#8 | 1.9%#2 |
| REGN | — | 21.3x#2 | — | — | 1.0%#12 | 2.1%#11 | 24.9%#7 | 13.4%#7 | 9.2%#9 | — | 47.6%#7 | — |
| ARGX | $54.5B#7 | — | — | 1532.4x#13 | 254.4%#1 | 55.1%#8 | 2965.7%#1 | — | — | — | 7.2%#13 | — |
| ALNY | $21.3B#14 | 8.3x#1 | 5.9x#4 | 5.7x#3 | 65.2%#3 | 212.8%#4 | 13.5%#10 | 8.7%#9 | 19.3%#6 | — | -65.2%#15 | — |
| NTRA | $56.8B#6 | — | 31.2x#11 | 24.6x#9 | 35.9%#5 | -9.3%#12 | -13.4%#12 | -11.4%#11 | -18.0%#10 | — | 98.2%#3 | — |
| RVMD | $40.4B#8 | — | 15.5x#8 | — | — | -88.5%#15 | — | -43.4%#13 | — | — | 220.3%#2 | — |
| BIIB | $37.1B#9 | 108.7x#8 | 2.5x#1 | 3.8x#1 | 2.2%#11 | -20.8%#13 | 28.7%#6 | 8.7%#8 | 12.3%#8 | 3#3 | 62.6%#5 | — |
| ILMN | $34.4B#10 | 39.2x#6 | 10.9x#6 | 7.9x#6 | -0.7%#13 | 169.5%#5 | 18.6%#9 | 27.0%#3 | 19.9%#5 | 8#1 | 84.3%#4 | — |
| MRNA | $89.0B#5 | — | 13.2x#7 | 45.8x#11 | -39.9%#14 | 20.8%#9 | -158.1%#13 | -41.7%#12 | -54.6%#11 | — | 720.7%#1 | — |
| ONC | $536.7B#1 | 844.5x#9 | 103.7x#13 | 100.5x#12 | 40.2%#4 | 144.5%#6 | 8.4%#11 | 5.5%#10 | 29.9%#2 | 6#2 | 16.5%#12 | — |
| INCY | $24.4B#12 | 61.1x#7 | 4.3x#3 | 4.7x#2 | 21.2%#6 | 3846.9%#1 | 29.5%#5 | 22.8%#4 | 45.1%#1 | — | 28.1%#11 | — |
| UTHR | $25.5B#11 | 21.3x#3 | 4.0x#2 | 8.0x#7 | 10.6%#7 | 11.7%#10 | 46.9%#2 | 20.9%#5 | — | — | 33.4%#9 | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice